Quick answer: Every clinical claim on GLP Agonists is reviewed against primary sources (FDA labeling, peer-reviewed literature, and official drug information) and is dated with a last-updated and, where relevant, last-reviewed date.
Medical Review Policy
Our medical review policy explains how health content on this site is checked, who reviews it, and how we keep it accurate and current.
Last updated June 12, 2026. Reviewed by the GLP Agonists editorial team.
How we review content
Health and pricing content is written by our editorial team and checked against primary sources: FDA prescribing information and safety communications, peer-reviewed clinical literature, and official manufacturer drug information. Clinical statements about eligibility, contraindications, dosing, and side effects are sourced to FDA labeling wherever such labeling exists. Editorial opinions and provider scoring are clearly separated from clinical facts.
Who reviews
Clinical content is reviewed by qualified members of our editorial and medical review team. Reviewer profiles and credentials are listed on our team page. Where a named clinician reviews a page, that is indicated on the page with a review date.
Update cadence
Money and pricing pages are re-checked regularly and carry a “last updated” and “last price checked” date. Clinical pages are reviewed when source guidance changes (for example, an FDA labeling update or shortage-list change) and at least periodically.
Corrections & conflicts
We correct errors promptly and transparently — see our corrections policy. Commercial relationships, including referral arrangements, are disclosed in our advertising disclosure and conflicts of interest statement, and they do not influence clinical facts or scoring.
Not medical advice
Compounded medication disclaimer. Compounded tirzepatide and semaglutide are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality the way brand-name Mounjaro®, Zepbound®, Ozempic®, or Wegovy® are. They are prepared by state-licensed 503A pharmacies or registered 503B outsourcing facilities for patients with a valid prescription. Pricing, availability, and legality can change with FDA shortage status. Verify current details with the provider at intake.
Compounded medication disclaimer. Compounded tirzepatide and semaglutide are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality the way brand-name Mounjaro®, Zepbound®, Ozempic®, or Wegovy® are. They are prepared by state-licensed 503A pharmacies or registered 503B outsourcing facilities for patients with a valid prescription. Pricing, availability, and legality can change with FDA shortage status. Verify current details with the provider at intake.
Frequently asked questions
Who medically reviews GLP Agonists content?
Clinical content is reviewed by qualified members of our editorial and medical review team against FDA labeling and peer-reviewed literature. Reviewer credentials are listed on our team page, and pages reviewed by a named clinician show a review date.
How often is content updated?
Pricing pages are re-checked regularly with last-updated and last-price-checked dates. Clinical pages are reviewed when source guidance changes and at least periodically.
Does GLP Agonists give medical advice?
No. Our content is educational and does not replace personalized advice from a licensed clinician. Eligibility and prescriptions are always determined by a licensed clinician.